AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to $1.

President Donald Trump has signed the HALT Fentanyl Act into law which gives law enforcement more power in the fight against ...

Governor Mike DeWine has called on the Ohio Board of Pharmacy to immediately classify all natural and synthetic kratom ...

Sudden death of 17-year-old girl and hospitalisations sparks fears of high-strength ecstasy as Electric Picnic approaches ...

AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major ...